A potential breakthrough in heart disease
Cambridge medics tested a low-dose drug that ⬇️inflammation in blood vessels by ⬆️ protective immune cells. This mechanism won the 2025 Nobel Prize for Medicine
Over 2 years Drug group: 0 events, placebo 11%
www.nature.com/articles/s41...

#HeartHealth

The IVORY trial was published in Nature Medicine last week. rdcu.be/eX8W3

This trial done in high-risk individuals who presented with heart attacks 🫀, showed low-dose interleukin-2 led to a
⬆️ Regulatory T cells
⬇️ Arterial inflammation 🔥
⬇️ trend in adverse cardiovascular outcomes ❤️‍🔥 at 2 years

Thank you @vpd-hlri.bsky.social for the shout-out.
Original article here:

rdcu.be/eX8W3

Original article:
rdcu.be/eX8W3

Pr Z Mallat @PARCC and colleagues show that, in patients with acute coronary syndromes, low-dose IL-2 safely increases Treg cell levels and reduces arterial inflammation.
Learn More: www.nature.com/articles/s41...

After 6 weeks of Rx patients with ACSs, low-dose IL-2 safely increases Tregcell levels and reduces arterial inflammation.
www.nature.com/articles/s41...

Delighted to share that the results of the IVORY trial were published in Nature Medicine: rdcu.be/eX8W3

This marks a significant scientific milestone for the field and the translational journey of low-dose IL-2.